Re: Ian D. Davis, Wanling Xie, Carmel Pezaro, et al. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol 2017;71:970-8 The Change in Baseline IMDC Prognostic Category: From the Past, Implications for the Future

Iacovelli Roberto; Artibani Walter; Tortora Giampaolo

首页> 外文期刊>European urology >Re: Ian D. Davis, Wanling Xie, Carmel Pezaro, et al. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol 2017;71:970-8 The Change in Baseline IMDC Prognostic Category: From the Past, Implications for the Future

【24h】

Re: Ian D. Davis, Wanling Xie, Carmel Pezaro, et al. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol 2017;71:970-8 The Change in Baseline IMDC Prognostic Category: From the Past, Implications for the Future

机译：Re：Ian D. Davis，Wanling谢，Carmel Pezaro，等。二线靶向治疗对肾细胞癌的疗效根据国际转移性肾细胞癌数据库联盟的基线变化。 EUR UROL 2017; 71：970-8基线IMDC预后类别的变化：从过去，对未来的影响

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European urology》 |2017年第6期|共2页
作者
Iacovelli Roberto; Artibani Walter; Tortora Giampaolo;
展开▼
作者单位

Azienda Osped Univ Integrata Med Oncol Unit Verona Italy;

Azienda Osped Univ Integrata Urol Unit Verona Italy;

Azienda Osped Univ Integrata Med Oncol Unit Verona Italy;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类泌尿科学（泌尿生殖系疾病）;
关键词

相似文献

外文文献

1. Re: Ian D. Davis, Wanling Xie, Carmel Pezaro, et al. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol 2017;71:970-8 The Change in Baseline IMDC Prognostic Category: From the Past, Implications for the Future [J] . Iacovelli Roberto, Artibani Walter, Tortora Giampaolo European urology . 2017,第6期

机译：Re：Ian D. Davis，Wanling谢，Carmel Pezaro，等。二线靶向治疗对肾细胞癌的疗效根据国际转移性肾细胞癌数据库联盟的基线变化。 EUR UROL 2017; 71：970-8基线IMDC预后类别的变化：从过去，对未来的影响
2. International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study [J] . Ko Jenny J., Xie Wanling, Kroeger Nils, The lancet oncology . 2015,第3期

机译：国际转移性肾细胞癌数据库联合会模型作为先前接受过一线靶向治疗的转移性肾细胞癌患者的预后工具：一项基于人群的研究
3. Re: Michal Sarfaty, Moshe Leshno, Noa Gordon, et al. Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.07.041 Second-line Treatment in Metastatic Renal Cell Carcinoma. Can Immunotherapy Be Considered a Cost-effective Treatment? [J] . Giuliani Jacopo, Bonetti Andrea European urology . 2018,第3期

机译：Re：Michal Sarfaty，Moshe Leshno，Noa Gordon等。晚期肾细胞癌中Nivolumab的成本效果。 EUR UROL。在新闻。 http://dx.doi.org/10.1016/j.eururo.2017.07.041二线治疗转移性肾细胞癌。可以免疫疗法被认为是具有成本效益的治疗方法吗？
4. Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC) [O] . Steven M. Yip, Jose M. Ruiz Morales, Frede Donskov, -1

机译：在靶向治疗时代的转移性嗜铬细胞肾细胞癌（chrRCC）的结果：国际转移性肾细胞癌数据库联盟（IMDC）的结果
5. Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC) [O] . Steven M. Yip, Jose M. Ruiz Morales, Frede Donskov, 2017

机译：靶向治疗时代的转移致染色体肾细胞癌（CHRRRCC）的结果：国际转移性肾细胞癌数据库联盟（IMDC）的结果

著录项

相似文献

相关主题

期刊订阅